Risk of recurrent venous thromboembolism according to baseline risk factor profiles
نویسندگان
چکیده
منابع مشابه
Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism.
Hyperhomocysteinemia is a risk factor of venous thromboembolism. The risk of recurrence in patients with hyperhomocysteinemia is unknown, and the optimal therapy for these patients after acute venous thromboembolism is uncertain. In a multicenter study, 264 patients with an objectively documented single episode of idiopathic venous thromboembolism were prospectively followed after discontinuati...
متن کاملNew risk factor for venous thromboembolism?
Thromb Haemost 2008; 100: 173–174 Venous thromboembolism (VTE), particularly recurrent VTE, presents an ongoing challenge to clinical management. Despite Virchow's original insight into the triad of blood stasis, vessel wall changes and hypercoagulability as the underlying causes of VTE (1), the identification of new risk factors for VTE has been problematic. Several well-validated genetic risk...
متن کاملD-dimer levels and risk of recurrent venous thromboembolism.
CONTEXT Widespread screening of patients with venous thromboembolism (VTE) for thrombophilic risk factors has become common clinical practice. Because of the increasing number of risk factors, assessing the risk of recurrence in an individual patient is intricate; therefore, a laboratory method that measures multifactorial thrombophilia is required. OBJECTIVE To prospectively study the relati...
متن کاملThe risk of recurrent venous thromboembolism in men and women.
BACKGROUND Whether a patient's sex is associated with the risk of recurrent venous thromboembolism is unknown. METHODS We studied 826 patients for an average of 36 months after a first episode of spontaneous venous thromboembolism and the withdrawal of oral anticoagulants. We excluded pregnant patients and patients with a deficiency of antithrombin, protein C, or protein S; the lupus anticoag...
متن کاملHigh-density lipoprotein and the risk of recurrent venous thromboembolism.
BACKGROUND High-density lipoprotein (HDL) protects against arterial atherothrombosis, but it is unknown whether it protects against recurrent venous thromboembolism. METHODS AND RESULTS We studied 772 patients after a first spontaneous venous thromboembolism (average follow-up 48 months) and recorded the end point of symptomatic recurrent venous thromboembolism, which developed in 100 of the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood Advances
سال: 2018
ISSN: 2473-9529,2473-9537
DOI: 10.1182/bloodadvances.2018017160